Interests in associates |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Interests in associates | |
| Interests in associates | 6. Interests in associates The European Commission’s, and subsequently the United Kingdom’s Medicines and Healthcare products Regulatory Agency’s, revocation of the TAVNEOS® marketing authorization led primarily to an impairment of intangible assets at Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) resulting in a decrease in the equity method investment’s profit in the amount of €173,342 for the nine months ended September 30, 2026 with a corresponding proportionate decrease in the Company’s income from equity method investees. The carrying amount of the Company’s investment increased by €14,364 from December 31, 2025 to September 30, 2026. |